@article{TEXTUAL,
      recid = {11035},
      author = {Sasaki, Koichi and Ishihara, Jun and Ishihara, Ako and  Miura, Risako and Mansurov, Aslan and Fukunaga, Kazuto and  Hubbell, Jeffrey A.},
      title = {Engineered collagen-binding serum albumin as a drug  conjugate carrier for cancer therapy},
      journal = {Science Advances},
      address = {2019-08-14},
      number = {TEXTUAL},
      abstract = {Serum albumin (SA) is used as a carrier to deliver  cytotoxic agents to tumors via passive targeting. To  further improve SA's tumor targeting capacity, we sought to  develop an approach to retain SA-drug conjugates within  tumors through a combination of passive and active  targeting. SA was recombinantly fused with a  collagen-binding domain (CBD) of von Willebrand factor to  bind within the tumor stroma after extravasation due to  tumor vascular permeability. Doxorubicin (Dox) was  conjugated to the CBD-SA via a pH-sensitive linker.  Dox-CBD-SA treatment significantly suppressed tumor growth  compared to both Dox-SA and aldoxorubicin treatment in a  mouse model of breast cancer. Dox-CBD-SA efficiently  stimulated host antitumor immunity, resulting in the  complete eradication of MC38 colon carcinoma when used in  combination with anti-PD-1 checkpoint inhibitor. Dox-CBD-SA  decreased adverse events compared to aldoxorubicin. Thus,  engineered CBD-SA could be a versatile and clinically  relevant drug conjugate carrier protein for treatment of  solid tumors.},
      url = {http://knowledge.uchicago.edu/record/11035},
}